Investor information

Stock chart

Symbol Date Last Change $ Change % Low High Avg. volume Mkt cap
Loading... - - - - - - - -

About Manhattan Scientifics, Inc.

The Company’s business model capitalizes on inventions and technology from which profits could be earned primarily through licensing. MHTX is dedicated to earning profit for its 8,600 owner-shareholders by identifying, developing, patenting, supporting and marketing technical innovation by harvesting top technology talent to bring game-changing products to market.

Manhattan Scientifics, Inc. is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nanomedical applications developed by Senior Scientific LLC, a unit of the Company.

Manhattan Scientifics, Inc.  assists and acquires early stage technologies and assists entrepreneurial founders and management to stage them to become commercial.

Our investment philosophy is defined by our desire to help build innovative companies with exceptional potential. We emphasize novel technologies in the nanomedicine space with the potential to be disruptive and the ability to establish sustainable businesses. We are patient capital with experienced business-building partners who bring the perspective of merchant-bankers not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune 1000 or larger). The entrepreneurial scientists and engineers who join us create personal success and wealth on an accelerated basis by virtue of ownership of publicly traded Manhattan Scientifics shares (MHTX).

SEC Filings

Access the company SEC Filings

Management Team

  • CEO Emmanuel (Manny) Tsoupanarias
  • Chairman and Founder Marvin Maslow
  • Director Leonard Friedman, Esq.
  • Director Frank Georgiou

Science and Technology Committee

  • Edward R. Flynn, Ph.D., Dr. Flynn is an expert in several diverse fields including nuclear physics, brain research and cancer research.
  • Mike Harsh, Former VP & Chief Technology Officer for GE Healthcare, a co-founder of Terapede Systems and has over 36 years of experience in healthcare technology, focused on diagnostic imaging.
  • Terry Lowe, Ph.D., has previously served as deputy director of the Materials Science and Technology division
  • Martin Cooper, Ph.D., 28 years chief technical officer with Motorola. "Father" of the cellular telephone. Cooper is founder of ArrayComm.
  • Donald J. Sandstrom, Ph.D., 42 years with Los Alamos National Laboratory. Materials Science Technology Division Leader.
  • Henry Rack, Ph.D., Dr. Rack received his B.S., M.S. and Sc.D in Metallurgy from MIT. Since 1985, Dr. Rack has been a Professor at the School of Materials Science and Engineering at Clemson University.

Downloads

Key company developments

  • Manhattan Scientifics and Senior Scientific File Provisional Patent on Early Cancer Detection System
  • Manhattan Scientifics Signs LOI to Acquire Rights to Early Cancer Detection System Developed by Dr. Edward R. Flynn
  • Manhattan Scientifics, Inc. Announces Exclusive License with Carpenter Technology Corporation
  • Manhattan Scientifics and Los Alamos National Laboratory Sign Licensing Partnership Agreement
  • FDA Approval Granted on New Titanium Dental Implant
  • Manhattan Scientifics Appoints Professor Henry J. Rack, Prominent Material Scientist to Its Research Team
  • Manhattan Scientifics Acquires Metallicum, Inc.
  • Art Kaufman to Join Manhattan Scientifics Science and Technology Committee
  • Manhattan announced a Letter of Intent to acquire Metallicum, Inc.
  • Manhattan announced its new CEO, Emmanuel (Manny) Tsoupanarias
  • Manhattan acquired 43 Million MHTX common shares from the Lancer Fund Trustee. Company raised $1.1 million in private placement of equity.
  • Manhattan raised new capital and new management to re-start operations.